Figure 521: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients with an infection



Figure 522: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients with sepsis



Figure 523: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients with adverse events other than osteomyelitis, infection and sepsis



Figure 524: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – mortality



I.2.7.41 Recombinant platelet-derived growth factor (300□g/g) versus placebo

Figure 525: Recombinant platelet-derived growth factor (300□g/g) versus placebo – proportion of patients completely healed

Figure 526: Recombinant platelet-derived growth factor (300□g/g) versus placebo – proportion of patients ≥ 90% healed



Figure 527: Recombinant platelet-derived growth factor (300□g/g) versus placebo – proportion of patients with osteomyelitis



Figure 528: Recombinant platelet-derived growth factor (300□g/g) versus placebo – proportion of patients with an infection



Figure 529: Recombinant platelet-derived growth factor (300µg/g) versus placebo – proportion of patients with sepsis

Study or Subgroup	PDGF-BB 300 Events	Total	Placebo Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Rees 1999	0	30	0	31		Not estimable
Total (95% CI)		**30**		**31**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 530: Recombinant platelet-derived growth factor (300µg/g) versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis



Figure 531: Recombinant platelet-derived growth factor (300µg/g) versus placebo –mortality



I.2.7.42 Recombinant platelet-derived growth factor: 1.0µg/g versus placebo

Figure 532: Recombinant platelet-derived growth factor: 1.0µg/g versus placebo – proportion of people completely healed



Figure 533: Recombinant platelet-derived growth factor: 1.0µg/g versus placebo – proportion of people with infection



Figure 534: Recombinant platelet-derived growth factor: 1.0 g/g versus placebo – mortality

Study or Subgroup	PDGF-BB 1.0 Events	Total	Placebo Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Robson 1992b	0	4	0	7		Not estimable
Total (95% CI)		**4**		**7**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



I.2.7.43 Recombinant platelet-derived growth factor-BB (1.0 g/g) vs. recombinant platelet-derived growth factor-BB (10.0 g/g)

Figure 535: Recombinant platelet-derived growth factor-BB (1.0 g/g) vs. recombinant platelet-derived growth factor-BB (10.0 g/g) – proportion of people with pressure ulcers completely healed

Study or Subgroup	PDGF-BB 1.0 Events	Total	PDGF-BB 10.0 Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1992b	0	4	0	4		Not estimable
Total (95% CI)		**4**		**4**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 536: Recombinant platelet-derived growth factor-BB (1.0 g/g) vs. recombinant platelet-derived growth factor-BB (10.0 g/g) – proportion of people with an infection

Study or Subgroup	PDGF-BB 1.0 Events	Total	PDGF-BB 10.0 Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1992b	0	4	0	4		Not estimable
Total (95% CI)		**4**		**4**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 537: Recombinant platelet-derived growth factor-BB (1.0 g/g) vs. recombinant platelet-derived growth factor-BB (10.0 g/g) - mortality

Study or Subgroup	PDGF-BB 1.0 Events	Total	PDGF-BB 10.0 Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1992b	0	4	0	4		Not estimable
Total (95% CI)		**4**		**4**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



I.2.7.44 Recombinant platelet-derived growth factor: 1.0 g/g versus 100.0 g/g

Figure 538: Recombinant platelet-derived growth factor: 1.0 g/g versus 100.0 g/g – proportion of patients completely healed



Figure 539: Recombinant platelet-derived growth factor: 1.0 g/g versus 100.0 g/g – proportion of patients with infection



Figure 540: Recombinant platelet-derived growth factor: 1.0 g/g versus 100.0 g/g – mortality



I.2.7.45 Recombinant platelet-derived growth factor-BB (10.0 g/g) versus placebo

Figure 541: Recombinant platelet-derived growth factor-BB (10.0 g/g) versus placebo – proportion of people with pressure ulcers completely healed



Figure 542: Recombinant platelet-derived growth factor-BB (10.0 g/g) versus placebo – proportion of people with infection



Figure 543: Recombinant platelet-derived growth factor-BB (10.0µg/g) versus placebo – mortality



I.2.7.46 Recombinant platelet-derived growth factor: 10.0µg/g versus 100.0µg/g

Figure 544: Recombinant platelet-derived growth factor: 10.0µg/g versus 100.0µg/g – proportion of patients completely healed



Figure 545: Recombinant platelet-derived growth factor: 10.0µg/g versus 100.0µg/g – proportion of patients with infection



Figure 546: Recombinant platelet-derived growth factor: 10.0µg/g versus 100.0µg/g – mortality



Figure 547: Recombinant platelet-derived growth factor (100.0µg/g) versus placebo – proportion of patients completely healed



Figure 548: Recombinant platelet-derived growth factor (100.0 g/g) versus placebo – mean percentage reduction in ulcer depth



Figure 549: Recombinant platelet-derived growth factor (100.0 g/g) versus placebo – mean percentage reduction in ulcer depth



Figure 550: Recombinant platelet-derived growth factor (100.0 g/g) versus placebo – proportion of people with infection



Figure 551: Recombinant platelet-derived growth factor (100.0 g/g) versus placebo – mortality



I.2.7.47 Basic fibroblast growth factor (different schedules and doses) versus placebo

Figure 552: Basic fibroblast growth factor (different schedules and doses) versus placebo – proportion of patients > 70% healed



Figure 553: Basic fibroblast growth factor (different schedules and doses) versus placebo – mortality



I.2.7.48 Interleukin 1-beta (0.01ug/cm^2) vs. placebo

Figure 554: Interleukin 1-beta (0.01µg/cm²) vs. placebo – proportion of people with pressure ulcers completely healed



Figure 555: Interleukin 1-beta (0.01µg/cm²) vs. placebo – mortality



I.2.7.49 Interleukin 1-beta (0.01µg/cm²) versus interleukin 1-beta (0.1µg/cm²)

Figure 556: Interleukin 1-beta (0.01µg/cm²) versus interleukin 1-beta (0.1µg/cm²) – proportion of people with pressure ulcers completely healed



Figure 557: Interleukin 1-beta (0.01□g/cm²) versus interleukin 1-beta (0.1□g/cm²) – mortality

Study or Subgroup	IL-1beta 0.01 Events	Total	IL-1beta 0.1 Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable
Total (95% CI)		**6**		**6**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



I.2.7.50 Interleukin 1-beta (0.01□g/cm²) vs. interleukin 1-beta (1.0□g/cm²) –

Figure 558: Interleukin 1-beta (0.01□g/cm²) vs. interleukin 1-beta (1.0□g/cm²) – proportion of people with pressure ulcers completely healed

Study or Subgroup	IL-1beta 0.01 Events	Total	IL-1beta 1.0 Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable
Total (95% CI)		**6**		**6**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 559: Interleukin 1-beta (0.01□g/cm²) vs. interleukin 1-beta (1.0□g/cm²) – mortality

Study or Subgroup	IL-1beta 0.01 Events	Total	IL-1beta 1.0 Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable
Total (95% CI)		**6**		**6**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



I.2.7.51 Interleukin 1-beta (0.1□g/cm²) vs. placebo

Figure 560: Interleukin 1-beta (0.1□g/cm²) vs. placebo – proportion of people with pressure ulcers completely healed

Study or Subgroup	IL-1beta 0.1 Events	Total	Placebo Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable
Total (95% CI)		**6**		**6**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 561: Interleukin 1-beta (0.1□g/cm²) vs. placebo – mortality

Study or Subgroup	IL-1beta 0.1 Events	Total	Placebo Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable
Total (95% CI)		**6**		**6**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



I.2.7.52 Interleukin 1-beta (0.1µg/cm²) vs. interleukin 1-beta (1.0µg/cm²)

Figure 562: Interleukin 1-beta (0.1µg/cm²) vs. interleukin 1-beta (1.0µg/cm²) – proportion of people with pressure ulcers completely healed



Figure 563: Interleukin 1-beta (0.1µg/cm²) vs. interleukin 1-beta (1.0µg/cm²) – mortality



I.2.7.53 Interleukin 1-beta (1.0µg/cm²) vs. placebo

Figure 564: Interleukin 1-beta (1.0µg/cm²) vs. placebo – proportion of people with pressure ulcers completely healed



Figure 565: Interleukin 1-beta (1.0µg/cm²) vs. placebo – mortality



I.2.7.54 Chlorinated lime solution versus dextranomer

Figure 566: Chlorinated lime solution versus dextranomer – Time to healing (defined as granulation and < 25% of original ulcer area) (days)



Figure 567: Chlorinated lime solution versus dextranomer – mortality



I.2.8 Dressings

Figure 568: Figure 2. Hydrocolloid dressing versus gauze dressing – proportion of patients completely healed



Figure 569: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (all stages – all sites)



Figure 570: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (stage II – all sites)



Figure 571: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (stage III – all sites)



Figure 572: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (all stages - sacral)



Figure 573: Hydrocolloid dressing versus gauze dressing – proportion of ulcers improved



Figure 574: Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (all stages)



Figure 575: Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (stage II)



Figure 576: Figure 10. Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (stage III)



Figure 577: Hydrocolloid dressing versus gauze dressing – mean percentage reduction in ulcer area



Figure 578: Figure 12. Hydrocolloid dressing versus gauze dressing – mean percentage reduction in ulcer volume



Figure 579: Hydrocolloid dressing versus gauze dressing – mean healing speed (mm²/day)



Figure 580: Hydrocolloid dressing versus gauze dressing – proportion of patients with an infection



Figure 581: Hydrocolloid dressing versus gauze dressing – proportion of patients with hypergranulation



Figure 582: Hydrocolloid dressing versus gauze dressing – proportion of patients with skin irritation



Figure 583: Hydrocolloid dressing versus gauze dressing – proportion of patients with pain at dressing removal



Figure 584: Figure 18. Hydrocolloid dressing versus gauze dressing – proportion of patients with discomfort



Figure 585: Hydrocolloid dressing versus gauze dressing – mortality



Figure 586: Hydrocolloid dressing versus foam dressing – proportion of patients completely healed



Figure 587: Hydrocolloid dressing versus foam dressing – proportion of patients improved



Figure 588: Hydrocolloid dressing versus foam dressing – proportion of patients not changed



Figure 589: Hydrocolloid dressing versus foam dressing – proportion of patients worsened



Figure 590: Hydrocolloid dressing versus foam dressing – mean reduction in ulcer area



Figure 591: Hydrocolloid dressing versus foam dressing – proportion of patients with bleeding



Figure 592: Hydrocolloid dressing versus foam dressing – proportion of patients with maceration



Figure 593: Hydrocolloid dressing versus foam dressing – proportion of patients with inflammation or maceration



Figure 594: Figure 27. Hydrocolloid dressing versus foam dressing – mean pain score at end of treatment



Figure 595: Hydrocolloid dressing versus foam dressing – mean odour score at end of treatment



Figure 596: Hydrocolloid dressing versus foam dressing – proportion of patients with adverse events (unknown if dressing related)



Figure 597: <Insert graphic title here>

<Click here and insert picture with the Graphic tools on the Toolbar Ribbon>

Figure 598: Hydrocolloid dressing versus foam dressing- mortality

Study or Subgroup	Hydrocolloid Events	Total	Foam Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Bale1997	2	31	6	29	100.0%	0.31 [0.07, 1.42]
Total (95% CI)		**31**		**29**	**100.0%**	**0.31 [0.07, 1.42]**
Total events	2		6			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)



Figure 599: Hydrocolloid dressing versus polyurethane dressing – proportion of patients completely healed

Study or Subgroup	Hydrocolloid Events	Total	Polyurethane Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
3.1.3 Polyurethane						
Banks 1994a	11	12	10	10	27.0%	0.93 [0.73, 1.17]
Banks 1994b	10	10	12	18	21.8%	1.45 [1.02, 2.06]
Brown-Etris 2008	22	37	21	35	51.2%	0.99 [0.68, 1.45]
Subtotal (95% CI)		**59**		**63**	**100.0%**	**1.07 [0.87, 1.33]**
Total events	43		43			

Heterogeneity: Chi² = 4.54, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 0.65 (P = 0.52)

Test for subgroup differences: Not applicable



Figure 600: Hydrocolloid dressing versus polyurethane dressing – proportion of patients improved

Study or Subgroup	Hydrocolloid Events	Total	Polyurethane Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
3.2.3 Polyurethane						
Banks 1994b	10	10	18	18	100.0%	1.00 [0.86, 1.16]
Subtotal (95% CI)		**10**		**18**	**100.0%**	**1.00 [0.86, 1.16]**
Total events	10		18			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

Test for subgroup differences: Not applicable



Figure 601: Hydrocolloid dressing versus polyurethane dressing – linear healing rate (cm/week)

Study or Subgroup	Hydrocolloid Mean	SD	Total	Polyurethane Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
3.5.1 Polyurethane								
Brown-Etris 2008	0.12	0.136	37	0.1	0.205	35	100.0%	0.02 [-0.06, 0.10]
Subtotal (95% CI)			**37**			**35**	**100.0%**	**0.02 [-0.06, 0.10]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.48 (P = 0.63)

Test for subgroup differences: Not applicable



Figure 602: Hydrocolloid dressing versus polyurethane dressing – mean odour score



Figure 603: Hydrocolloid dressing versus polyurethane dressing – mean comfort score



Figure 604: Hydrocolloid dressing versus polyurethane dressing – mortality



Figure 605: Hydrocolloid dressing versus collagenase ointment – proportion of patients completely healed



Figure 606: Hydrocolloid dressing versus collagenase ointment – mean percentage reduction in ulcer area



Figure 607: Hydrocolloid dressing versus collagenase ointment – mean cm² reduction in ulcer area



Figure 608: Hydrocolloid dressing versus collagenase ointment – mean time to healing (weeks)



Figure 609: Figure 39. Hydrocolloid dressing versus collagenase ointment – proportion of patients with adverse events



Figure 610: Hydrocolloid dressing versus collagenase ointment –mortality

Study or Subgroup	Hydrocolloid Events	Hydrocolloid Total	Collagen Events	Collagen Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Burgos 2000a	1	19	3	18	100.0%	0.32 [0.04, 2.76]
Total (95% CI)		**19**		**18**	**100.0%**	**0.32 [0.04, 2.76]**
Total events	1		3			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.04 (P = 0.30)



Figure 611: Hydrocolloid dressing versus collagen dressing – proportion of patients completely healed

Study or Subgroup	Hydrocolloid Events	Hydrocolloid Total	Collagen Events	Collagen Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Graumlich 2003	15	30	18	35	100.0%	0.97 [0.60, 1.57]
Total (95% CI)		**30**		**35**	**100.0%**	**0.97 [0.60, 1.57]**
Total events	15		18			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.11 (P = 0.91)



Figure 612: Hydrocolloid dressing versus collagen dressing – mean percentage reduction in ulcer area

Study or Subgroup	Hydrocolloid Mean	Hydrocolloid SD	Hydrocolloid Total	Collagen Mean	Collagen SD	Collagen Total	Weight	Mean Difference IV, Fixed, 95% CI
Graumlich 2003	9	73.98	30	33	73.98	35	100.0%	-24.00 [-60.08, 12.08]
Total (95% CI)			**30**			**35**	**100.0%**	**-24.00 [-60.08, 12.08]**

Heterogeneity: Not applicable
Test for overall effect: Z = 1.30 (P = 0.19)



Figure 613: Hydrocolloid dressing versus collagen dressing – mean speed of healing (mm²/day)

Study or Subgroup	Hydrocolloid Mean	Hydrocolloid SD	Hydrocolloid Total	Collagen Mean	Collagen SD	Collagen Total	Weight	Mean Difference IV, Fixed, 95% CI
Graumlich 2003	6	16	35	6	19	35	100.0%	0.00 [-8.23, 8.23]
Total (95% CI)			**35**			**35**	**100.0%**	**0.00 [-8.23, 8.23]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Figure 614: Figure 43. Hydrocolloid dressing versus collagen dressing – mean time to healing (weeks)

Study or Subgroup	Hydrocolloid Mean	Hydrocolloid SD	Hydrocolloid Total	Collagen Mean	Collagen SD	Collagen Total	Weight	Mean Difference IV, Random, 95% CI
Graumlich 2003	6	2.68	30	5	2.91	35	100.0%	1.00 [-0.36, 2.36]
Total (95% CI)			**30**			**35**	**100.0%**	**1.00 [-0.36, 2.36]**

Heterogeneity: Not applicable
Test for overall effect: Z = 1.44 (P = 0.15)



Figure 615: Hydrocolloid dressing versus collagen dressing – proportion of people with adverse events



Figure 616: Hydrocolloid dressing versus collagen dressing – mortality



Figure 617: Figure 44. Hydrocolloid dressing versus hydrogel dressing – proportion of patients completely healed



Figure 618: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers completely healed



Figure 619: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers not changed

Study or Subgroup	Hydrocolloid Events	Total	Hydrogel Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
5.3.1 Hydrogel						
Darkovich 1990	8	67	5	62	100.0%	1.48 [0.51, 4.28]
Subtotal (95% CI)		**67**		**62**	**100.0%**	**1.48 [0.51, 4.28]**
Total events	8		5			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.72 (P = 0.47)



Test for subgroup differences: Not applicable

Figure 620: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers worsened

Study or Subgroup	Hydrocolloid Events	Total	Hydrogel Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
5.4.2 Hydrogel						
Darkovich 1990	7	67	1	62	100.0%	6.48 [0.82, 51.16]
Subtotal (95% CI)		**67**		**62**	**100.0%**	**6.48 [0.82, 51.16]**
Total events	7		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.77 (P = 0.08)



Figure 621: Hydrocolloid dressing versus hydrogel dressing – mean percentage reduction in ulcer area (stage II)

Study or Subgroup	Hydrocolloid Mean	SD	Total	Hydrogel Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
5.6.1 Hydrogel								
Darkovich 1990	34	47.7	36	64	47.7	35	100.0%	-30.00 [-52.19, -7.81]
Subtotal (95% CI)			**36**			**35**	**100.0%**	**-30.00 [-52.19, -7.81]**

Heterogeneity: Not applicable
Test for overall effect: Z = 2.65 (P = 0.008)



Figure 622: Hydrocolloid dressing versus hydrogel dressing – mean healing rate (cm/day)

Study or Subgroup	Hydrocolloid Mean	SD	Total	Hydrogel Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
5.8.1 Hydrogel								
Motta 1999	0.35	0.43	5	0.15	0.22	5	100.0%	0.20 [-0.22, 0.62]
Subtotal (95% CI)			**5**			**5**	**100.0%**	**0.20 [-0.22, 0.62]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.93 (P = 0.35)



Test for subgroup differences: Not applicable

Figure 623: Hydrocolloid dressing versus hydrogel dressing – mortality (all-cause)



Figure 624: Hydrocolloid dressing versus impregnated gauze dressing – proportion of patients completely healed



Figure 625: Hydrocolloid dressing versus impregnated gauze dressing – proportion of patients improved



Figure 626: Hydrocolloid dressing versus poly-hema dressing – proportion of patients completely healed



Figure 627: Hydrocolloid dressing versus poly-hema dressing – absolute rate of healing (cm²/week)

Study or Subgroup	Hydrocolloid Mean	SD	Total	Poly-hema Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
7.3.1 Poly-hema								
Brod 1990	0.1	0.085	16	0.18	0.085	27	100.0%	-0.08 [-0.13, -0.03]
Subtotal (95% CI)			**16**			**27**	**100.0%**	**-0.08 [-0.13, -0.03]**

Heterogeneity: Not applicable
Test for overall effect: Z = 2.98 (P = 0.003)



Test for subgroup differences: Not applicable

Figure 628: Hydrocolloid dressing versus poly-hema dressing – proportion of patients with adverse events

Study or Subgroup	Hydrocolloid Events	Total	Poly-hema Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
7.4.1 Poly-hema						
Brod 1990	1	16	0	27	100.0%	14.69 [0.25, 847.55]
Subtotal (95% CI)		**16**		**27**	**100.0%**	**14.69 [0.25, 847.55]**
Total events	1		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.30 (P = 0.19)



Test for subgroup differences: Not applicable

Figure 629: Hydrocolloid dressing versus poly-hema dressing – mortality

Study or Subgroup	Hydrocolloid Events	Total	Poly-hema Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Brod 1990	1	16	2	27	100.0%	0.84 [0.08, 8.58]
Total (95% CI)		**16**		**27**	**100.0%**	**0.84 [0.08, 8.58]**
Total events	1		2			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.14 (P = 0.89)



Figure 630: Hydrocolloid dressing versus co-polymer (amino acid) dressing – proportion of patients completely healed

Study or Subgroup	Hydrocolloid Events	Total	Co-polymer Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
8.1.8 Copolymer (amino acid)						
Hondé 1994	23	88	31	80	100.0%	0.67 [0.43, 1.05]
Subtotal (95% CI)		**88**		**80**	**100.0%**	**0.67 [0.43, 1.05]**
Total events	23		31			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.73 (P = 0.08)



Test for subgroup differences: Not applicable

Figure 631: Hydrocolloid dressing versus co-polymer (amino acid) dressing – proportion of patients with an infection



Figure 632: Hydrocolloid dressing versus phenytoin cream – proportion of patients completely healed



Figure 633: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers completely healed (all stages – all sites)



Figure 634: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers improved



Figure 635: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers worsened



Figure 636: Hydrocolloid dressing versus phenytoin cream – mortality (all-cause)



Figure 637: Hydrocolloid dressing versus alginate dressing – proportion of patients 40% healed



Figure 638: Hydrocolloid dressing versus alginate dressing – mean percentage reduction in ulcer area



Figure 639: Hydrocolloid dressing versus alginate dressing – mean cm² reduction in ulcer area

Study or Subgroup	Hydrocolloid Mean	SD	Total	Alginate Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
10.3.2 Alginate								
Belmin 2002	5.2	7.2	53	9.7	7.1	57	100.0%	-4.50 [-7.17, -1.83]
Subtotal (95% CI)			**53**			**57**	**100.0%**	**-4.50 [-7.17, -1.83]**

Heterogeneity: Not applicable
Test for overall effect: Z = 3.30 (P = 0.0010)

Test for subgroup differences: Not applicable



Figure 640: Hydrocolloid dressing versus alginate dressing – proportion of patients with an infection

Study or Subgroup	Hydrocolloid Events	Total	Alginate Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
10.4.2 Alginate						
Belmin 2002	0	53	1	57	100.0%	0.15 [0.00, 7.34]
Subtotal (95% CI)		**53**		**57**	**100.0%**	**0.15 [0.00, 7.34]**
Total events	0		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.33)

Test for subgroup differences: Not applicable



Figure 641: Hydrocolloid dressing versus alginate dressing – proportion of patients with skin irritation

Study or Subgroup	Hydrocolloid Events	Total	Alginate Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
10.5.2 Alginate						
Belmin 2002	0	53	2	57	100.0%	0.14 [0.01, 2.31]
Subtotal (95% CI)		**53**		**57**	**100.0%**	**0.14 [0.01, 2.31]**
Total events	0		2			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.37 (P = 0.17)



Figure 642: Hydrocolloid dressing versus alginate dressing – proportion of patients with hypergranulation

Study or Subgroup	Hydrocolloid Events	Total	Alginate Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
10.6.3 Alginate						
Belmin 2002	5	53	1	57	100.0%	5.38 [0.65, 44.54]
Subtotal (95% CI)		**53**		**57**	**100.0%**	**5.38 [0.65, 44.54]**
Total events	5		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.56 (P = 0.12)